Clinical Scorecard: Texas First for Epioxa Therapy
At a Glance
| Category | Detail |
|---|---|
| Condition | Keratoconus |
| Key Mechanisms | Epioxa uses bioactivated riboflavin drops and UV light to strengthen corneal collagen while preserving the epithelium. |
| Target Population | Individuals aged 13 to 28 with keratoconus. |
| Care Setting | Ophthalmology practice |
Key Highlights
- Epioxa is an FDA-approved epithelium-on corneal cross-linking therapy.
- Preserves corneal epithelium to reduce discomfort and recovery time.
- Aims to slow or halt keratoconus progression, potentially preventing corneal transplantation.
- First offered in Texas by Dr. Yasir Ahmed at the Eye Center of Texas.
- Reflects a shift toward less invasive keratoconus treatments.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of keratoconus typically involves corneal topography and visual acuity assessments.
Management
- Consider corneal cross-linking for progressive keratoconus to stabilize the cornea.
Monitoring & Follow-up
- Regular follow-up to assess corneal stability and visual acuity post-treatment.
Risks
- Potential complications include infection, corneal haze, and visual disturbances.
Patient & Prescribing Data
Patients with progressive keratoconus, particularly those aged 13 to 28.
Epioxa aims to improve patient comfort and recovery time compared to traditional methods.
Clinical Best Practices
- Utilize Epioxa for eligible patients to enhance treatment experience.
- Educate patients on the benefits and risks of corneal cross-linking.
- Implement regular monitoring protocols post-treatment to ensure corneal health.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
